2025 · 2nd Quarter (Apr 1 - June 30)

JAZZ PHARMACEUTICALS, INC.

Filed by JAZZ PHARMACEUTICALS, INC..

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2025
Income: Not reported
Expenses: $370,000.00
Registrant: JAZZ PHARMACEUTICALS, INC.
Client: JAZZ PHARMACEUTICALS, INC.
Filing UUID: 0aa616e5-b462-4417-ab1b-9828faf659d2
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

FDA regulation of CBD Issues related to the regulation of cannabis and CBD, research and development of cannabis-derived therapies Farm, Food, and National Security Act Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act Drug safety, prescription drug abuse, value of prescription drugs Changes to the Inflation Reduction Act HR 946: Orphan Cures Act

Literal federal measure citations: HR 946

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.